Biogen Leans On Pipeline As Tecfidera, Spinraza See Q4 Sales Dip

Aducanumab Added To 2021 Guidance Amid Approval Optimism

 
• By Alaric DeArment
  
Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg
Biogen leans on aducanumab and other pipeline drugs as sales of Tecfidera and Spinraza slumped in Q4 and 2020. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip